<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2102221744
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RISEK 40MG INJ
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OMEPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Risek</strong> contains the active substance omeprazole. It belongs to a group of medicines called &lsquo;proton pump inhibitors&rsquo;. They work by reducing the amount of acid that your stomach produces.</p><p><strong>Risek</strong> powder for solution for injection can be used as an alternative to oral therapy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given Risek </strong></p><p>&middot;&nbsp;&nbsp; if you are allergic to omeprazole or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp; if you are allergic to other proton pump inhibitor medicines (e.g. pantoprazole, lansoprazole, rabeprazole, esomeprazole).</p><p>&middot;&nbsp;&nbsp; if you are taking a medicine containing nelfinavir (used for HIV infection).</p><p>You should not be given <strong>Risek</strong> if any of the above apply to you. If you are not sure, talk to your doctor, nurse or pharmacist before you are given this medicine.</p><p><strong>Warnings and precautions</strong></p><p><strong>Risek</strong> may hide the symptoms of other diseases. Therefore, if any of the following happen to you before you are given <strong>Risek</strong> or after you are given it, talk to your doctor straight away:</p><p>&middot;&nbsp;&nbsp; You lose a lot of weight for no reason and have problems swallowing.</p><p>&middot;&nbsp;&nbsp; You get stomach pain or indigestion.</p><p>&middot;&nbsp;&nbsp; You begin to vomit food or blood.</p><p>&middot;&nbsp;&nbsp; You pass black stools (blood-stained faeces).</p><p>&middot;&nbsp;&nbsp; You experience severe or persistent diarrhoea, as omeprazole has been associated with a small increase in infectious diarrhoea.</p><p>&middot;&nbsp;&nbsp; You have severe liver problems.</p><p>&middot;&nbsp;&nbsp; You are due to have a specific blood test (Chromogranin A).</p><p>&middot;&nbsp;&nbsp; You have ever had a skin reaction after treatment with a medicine similar to Omeprazole that reduces stomach acid.</p><p>If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with &nbsp;Omeprazole. Remember to also mention any other ill-effects like pain in your joints.</p><p>Taking a proton pump inhibitor like omeprazole, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).</p><p>This medicine may affect the way that your body absorbs vitamin B<sub>12</sub>, particularly if you need to take it for a long time. Please contact your doctor if you notice any of the following symptoms, which could indicate low levels of Vitamin B<sub>12</sub>:</p><p>&middot;&nbsp;&nbsp; Extreme tiredness or lack of energy</p><p>&middot;&nbsp;&nbsp; Pins and needles</p><p>&middot;&nbsp;&nbsp; Sore or red tongue, mouth ulcers</p><p>&middot;&nbsp;&nbsp; Muscle weakness</p><p>&middot;&nbsp;&nbsp; Disturbed vision</p><p>&middot;&nbsp;&nbsp; Problems with memory, confusion, depression.</p><p>When taking omeprazole, inflammation in your kidney may occur. Signs and symptoms may include decreased volume of urine or blood in your urine and/or hypersensitivity reactions such as fever, rash, and joint stiffness. You should report such signs to the treating physician.</p><p><strong>Children and adolescents</strong></p><p>This medicine should not be given to children and adolescents under 18 years of age. There is limited experience with omeprazole for intravenous use in children.</p><p><strong>Other medicines and Risek </strong></p><p>Tell your doctor, nurse or pharmacist if you are taking, have recently taken, or might take any other medicines including medicines obtained without a prescription. This is because <strong>Risek</strong> can affect the way some medicines work and some medicines can have an effect on <strong>Risek</strong>.</p><p>You<strong> must not be given</strong> <strong>Risek</strong> if you are taking a medicine containing&nbsp;nelfinavir (used to treat HIV infection)</p><p><strong>Tell your doctor, nurse or pharmacist if you are taking any of the following medicines:</strong></p><p>&middot;&nbsp;&nbsp; Ketoconazole, itraconazole, posaconazole or voriconazole (used to treat infections caused by a fungus).</p><p>&middot;&nbsp;&nbsp; Digoxin (used to treat heart problems).</p><p>&middot;&nbsp;&nbsp; Diazepam (used to treat anxiety, relax muscles or in epilepsy).</p><p>&middot;&nbsp;&nbsp; Phenytoin (used in epilepsy). If you are taking phenytoin, your doctor will need to monitor you when you start or stop taking <strong>Risek</strong>.</p><p>&middot;&nbsp;&nbsp; Medicines that are used to thin your blood, such as warfarin or other vitamin K blockers. Your doctor may need to monitor you when you start or stop taking <strong>Risek</strong>.</p><p>&middot;&nbsp;&nbsp; Rifampicin (used to treat tuberculosis).</p><p>&middot;&nbsp;&nbsp; Atazanavir (used to treat HIV infection).</p><p>&middot;&nbsp;&nbsp; Tacrolimus (in cases of organ transplantation).</p><p>&middot;&nbsp;&nbsp; St John&rsquo;s wort (<em>Hypericum perforatum</em>) (used to treat mild depression).</p><p>&middot;&nbsp;&nbsp; Cilostazol (used to treat intermittent claudication).</p><p>&middot;&nbsp;&nbsp; Saquinavir (used to treat HIV infection).</p><p>&middot;&nbsp;&nbsp; Clopidogrel (used to prevent blood clots (thrombi)).</p><p>&middot;&nbsp;&nbsp; Erlotinib (used to treat cancer).</p><p>&middot;&nbsp;&nbsp; Methotrexate (a chemotherapy medicine used in high doses to treat cancer) &ndash; if you are taking a high dose of methotrexate, your doctor may temporarily stop your <strong>Risek</strong> treatment.</p><p>If your doctor has prescribed the antibiotics amoxicillin and clarithromycin as well as <strong>Risek</strong> to treat ulcers caused by <em>Helicobacter pylori</em>&nbsp;infection, it is very important that you tell your doctor about any other medicines you are taking.</p><p><strong>Pregnancy and breastfeeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, nurse or pharmacist for advice before you are given this medicine.</p><p>Omeprazole is excreted in breast milk but is not likely to influence the child when therapeutic doses are used. Your doctor will decide whether you can take <strong>Risek</strong> if you are breastfeeding.</p><p><strong>Driving and using machines</strong></p><p><strong>Risek</strong> is not likely to affect your ability to drive or use any tools or machines. Side effects such as dizziness and visual disturbances may occur (see section 4). If affected, you should not drive or operate machinery.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp; <strong>Risek</strong> can be given to adults including the elderly.</p><p>&middot;&nbsp;&nbsp; There is limited experience with omeprazole for intravenous use in children.</p><p><strong>Being given Risek</strong></p><p>&middot;&nbsp;&nbsp; <strong>Risek</strong> will be given to you by a doctor who will decide how much you need.</p><p>&middot;&nbsp;&nbsp; The medicine will be given to you as an infusion into one of your veins.</p><p><strong>If you are given more Risek than you should</strong></p><p>If you think you have been given too much <strong>Risek</strong>, talk to your doctor straight away.</p><p><strong>If you have any further questions on the use of this product ask your doctor, nurse or pharmacist. </strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, <strong>Risek</strong> can cause side effects, although not everybody gets them.</p><p><strong>If you notice any of the following rare but serious side effects, stop using Risek and contact a doctor immediately:</strong></p><p>&middot;&nbsp;&nbsp; Sudden wheezing, swelling of your lips, tongue and throat or body, rash, fainting or difficulties to swallow (severe allergic reaction).</p><p>&middot;&nbsp;&nbsp; Reddening of the skin with blisters or peeling. There may also be severe blisters and bleeding in the lips, eyes, mouth, nose and genitals. This could be &lsquo;Stevens-Johnson syndrome&rsquo; or &lsquo;toxic epidermal necrolysis&rsquo;.</p><p>&middot;&nbsp;&nbsp; Yellow skin, dark urine and tiredness which can be symptoms of liver problems.</p><p><strong>Other side effects include:</strong></p><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp; Effects on your stomach or gut: diarrhoea, stomach pain, constipation, winds (flatulence)</p><p>&middot;&nbsp;&nbsp; benign polyps in the stomach</p><p>&middot;&nbsp;&nbsp; Feeling sick (nausea) or being sick (vomiting)</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>&middot;&nbsp;&nbsp; Swelling of the feet and ankles</p><p>&middot;&nbsp;&nbsp; Disturbed sleep (insomnia)</p><p>&middot;&nbsp;&nbsp; Dizziness, tingling feelings such as &ldquo;pins and needles&rdquo;, feeling sleepy</p><p>&middot;&nbsp;&nbsp; Spinning feeling (vertigo)</p><p>&middot;&nbsp;&nbsp; Changes in blood tests that check how the liver is working</p><p>&middot;&nbsp;&nbsp; Skin rash, lumpy rash (hives) and itchy skin</p><p>&middot;&nbsp;&nbsp; Generally feeling unwell and lacking energy</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people)</strong></p><p>&middot;&nbsp;&nbsp; Blood problems such as a reduced number of white cells or platelets. This can cause weakness, bruising or make infections more likely</p><p>&middot;&nbsp;&nbsp; Allergic reactions, sometimes very severe, including swelling of the lips, tongue and throat, fever, wheezing.</p><p>&middot;&nbsp;&nbsp; Low levels of sodium in the blood. This may cause weakness, being sick (vomiting) and cramps.</p><p>&middot;&nbsp;&nbsp; Feeling agitated, confused or depressed</p><p>&middot;&nbsp;&nbsp; Taste changes</p><p>&middot;&nbsp;&nbsp; Eyesight problems such as blurred vision</p><p>&middot;&nbsp;&nbsp; Suddenly feeling wheezy or short of breath (bronchospasm)</p><p>&middot;&nbsp;&nbsp; Dry mouth</p><p>&middot;&nbsp;&nbsp; An inflammation of the inside of the mouth</p><p>&middot;&nbsp;&nbsp; An infection called &ldquo;thrush&rdquo; which can affect the gut and is caused by a fungus</p><p>&middot;&nbsp;&nbsp; Liver problems, including jaundice which can cause yellow skin, dark urine, and tiredness</p><p>&middot;&nbsp;&nbsp; Hair loss (alopecia)</p><p>&middot;&nbsp;&nbsp; Skin rash on exposure to sunshine</p><p>&middot;&nbsp;&nbsp; Joint pains (arthralgia) or muscle pains (myalgia)</p><p>&middot;&nbsp;&nbsp; Severe kidney problems (interstitial nephritis)</p><p>&middot;&nbsp;&nbsp; Increased sweating</p><p><strong>Very rare side effects (may affect up to 1 in 10,000 people)</strong></p><p>&middot;&nbsp;&nbsp; Changes in blood count including agranulocytosis (lack of white blood cells)</p><p>&middot;&nbsp;&nbsp; Aggression</p><p>&middot;&nbsp;&nbsp; Seeing, feeling or hearing things that are not there (hallucinations)</p><p>&middot;&nbsp;&nbsp; Severe liver problems leading to liver failure and inflammation of the brain</p><p>&middot;&nbsp;&nbsp; Sudden onset of a severe rash or blistering or peeling skin. This may be associated with a high fever and joint pains (Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis)</p><p>&middot;&nbsp;&nbsp; Muscle weakness</p><p>&middot;&nbsp;&nbsp; Enlarged breasts in men.</p><p><strong>Side effects with unknown frequency (frequency cannot be estimated from the available data)</strong></p><p>&middot;&nbsp;&nbsp; Inflammation of the gut which causes diarrhoea</p><p>&middot;&nbsp;&nbsp; Rash, possibly with pain in the joints</p><p>&middot;&nbsp;&nbsp; If you are on Risek for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness or increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium</p><p>Irreversible visual impairment has been reported in isolated cases of critically ill patients who have received Omeprazole<strong> </strong>intravenous injection, especially at high doses, but no causal relationship has been established.</p><p>Omeprazole<strong> </strong>may in very rare cases affect the white blood cells leading to immune deficiency. If you have an infection with symptoms such as fever with a severely&nbsp;reduced general condition or fever with symptoms of a local infection such as pain in the neck, throat or mouth or difficulties in urinating, you must<strong> consult your doctor as soon as possible</strong> so that a lack of white blood cells (agranulocytosis) can be ruled out by a blood test. It is important for you to give information about your medicine at this time.</p><p>&nbsp;</p><p><strong><u>Reporting of side effects</u></strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.&nbsp;&nbsp;</p><p>You can also report side effects directly via:</p><p><strong>&bull;&nbsp;&nbsp; Saudi Arabia:</strong></p><p><strong>&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</strong></p><p><strong>&nbsp; -&nbsp;&nbsp; Fax: </strong>+966-11-205-7662</p><p><strong>&nbsp; -&nbsp;&nbsp; SFDA Call Centre:</strong> 19999</p><p><strong>&nbsp; -&nbsp;&nbsp; E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>&nbsp; -&nbsp;&nbsp; Website: </strong>https://ade.sfda.gov.sa</p><p><strong>&bull;&nbsp;&nbsp; Other GCC States:</strong></p><p><strong>&nbsp; -&nbsp; </strong>Please contact the relevant competent authority.</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>-&nbsp;&nbsp; Do not use <strong>Risek</strong> after the expiry date which is stated on the box and vial label after EXP. The expiry date refers to the last day of that month.</p><p>-&nbsp;&nbsp; Before reconstitution, store below<em> </em>30&deg;C, protected from light. After reconstitution, see &ldquo;<strong>Stability after Reconstitution</strong>&rdquo;.</p><p>-&nbsp;&nbsp; Do not use <strong>Risek</strong> if you notice any visible sign of deterioration.</p><p>-&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is omeprazole. Each vial contains lyophilized (freeze-dried)<em> </em>omeprazole sodium equivalent to omeprazole 40 mg.</p><p>The other ingredients: Sodium hydroxide.</p><p>&nbsp;</p><p><strong>The following information is intended for medical or healthcare professionals only:</strong></p><p>The entire contents of each <strong>Risek</strong> vial is to be dissolved in approximately 5 mL and then immediately diluted to 100mL. Sodium chloride 9 mg/mL (0.9%) solution for infusion or dextrose 50 mg/mL (5%) solution for infusion must be used. The stability of omeprazole is influenced by the pH of the solution for infusion, which is why no other solvent or quantities should be used for dilution.</p><p>The reconstituted solutions of <strong>Risek</strong> should be given as an <em>intravenous infusion</em> (over a period of 20 - 30 minutes).</p><p>&nbsp;</p><p><strong><u>Preparation</u></strong></p><p>1.&nbsp;&nbsp;&nbsp; With a syringe draw 5 mL of infusion solution from the 100 mL infusion bottle or bag.</p><p>2.&nbsp;&nbsp;&nbsp; Add this volume to the <strong>Risek</strong> vial, mix thoroughly making sure all omeprazole is dissolved.</p><p>3.&nbsp;&nbsp;&nbsp; Draw the omeprazole solution back into the syringe.</p><p>4.&nbsp;&nbsp;&nbsp; Transfer the solution into the infusion bag or bottle.</p><p>5.&nbsp;&nbsp;&nbsp; Repeat steps 1-4 to make sure all omeprazole is transferred from the vial into the infusion bag or bottle.</p><p><strong><u>Dosage</u></strong></p><p>40 mg once daily is recommended. In patients with Zollinger-Ellison Syndrome, 60 mg once daily is the recommended starting dose. Doses exceeding 60 mg daily should be divided and given twice daily.</p><p><strong>Hepatic impairment:</strong> A daily dose of 10-20 mg may be sufficient.</p><p><strong><u>Stability after Reconstitution:</u></strong></p><p>Chemical and physical in-use stability has been demonstrated for 12 hours at 30&deg;C, after reconstitution with sodium chloride 9 mg/mL (0.9%)<br />solution for infusion and for 6 hours at 30&deg;C, after reconstitution with dextrose 50 mg/mL (5%) solution for infusion.</p><p>From a microbiological point of view, the product should be used immediately unless it has been reconstituted under controlled and validated aseptic conditions.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Risek is available in packs of 1 or 10 vials each. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                25/07/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي <strong>رايسك</strong> على المادة الفعالة أوميبرازول التي تنتمي إلى مجموعة من الأدوية تعرف باسم &lsquo;مثبطات مضخة البروتون&rsquo;. تعمل هذه الأدوية على تقليل&nbsp; كمية الحمض الذي تفرزه المعدة.</p><p dir="RTL">يستعمل مسحوق <strong>رايسك </strong>لتحضير محلول للتسريب الوريدي كبديل للعلاج عن طريق الفم.<strong>&nbsp; </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم إعطاء رايسك في الحالات التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية تجاه أوميبرازول أو أياً&nbsp; من المكونات الأخرى في هذا الدواء (المذكورة في البند رقم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية تجاه الأدوية الأخرى المثبطة لمضخة البروتون (على سبيل المثال بانتوبرازول، لانسوبرازول، رابيبرازول وإيسوميبرازول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أحد الأدوية الحاوية على نيلفينافير (يستخدم لعلاج فيروس نقص المناعة البشريةالمكتسبة).</p><p dir="RTL">يجب أن لا يتم إعطائك <strong>رايسك</strong> في حال كان أياً مما ذكر أعلاه ينطبق عليك. يرجى منك الرجوع إلى طبيبك المعالج، الممرض أو الصيدلي الذي تتعامل معه قبل أن يتم إعطائك هذا الدواء في حال لم تكن متأكداّ من ذلك.</p><p dir="RTL"><strong>تحذيرات واحتياطات </strong></p><p dir="RTL">من المحتمل أن يخفي <strong>رايسك</strong> بعض الأعراض المصاحبة للأمراض الأخرى، لذلك، يرجى منك التحدث إلى طبيبك المعالج على الفور، إذا عانيت من أي مما يلي قبل أو بعد أن يتم إعطائك <strong>رايسك</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا عانيت من فقدان الكثير من الوزن دون أية أسباب وإذا كنت تعاني من مشاكل في البلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا عانيت من ألم في المعدة أو عسر الهضم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا بدأت في تقيؤ الطعام أو تقيؤ دموي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; في حال التبرز براز أسود اللون (البراز المصحوب بظهور دم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من إسهال&nbsp; شديد أو مستمر، حيث أن العلاج باستخدام أوميبرازول يصاحبه زيادة طفيفة في حدوث الإسهال الناتج عن العدوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل شديدة في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت سوف تخضع لإجراء فحوصات الدم (كروموجرانين أ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا عانيت مسبقاً من تفاعلات جلدية بعد تلقي العلاج باستخدام أحد الأدوية المماثلة لدواء<strong> رايسك </strong>التي تعمل على تقليل كمية حمض المعدة.</p><p dir="RTL">يرجى منك إخبار طبيبك المعالج في أقرب وقت ممكن في حال حدوث طفح جلدي وبصفة خاصة المناطق المعرضة إلى أشعة الشمس، فقد تكون بحاجة إلى التوقف عن تلقي العلاج باستخدام <strong>رايسك</strong>. كما يرجى منك إخبار طبيبك المعالج عن أية أعراض أخرى على سبيل المثال الشعور بالألم في المفاصل.</p><p dir="RTL">إن تناول مثبطات مضخات البروتون مثل أوميبرازول، وبصفة خاصة على مدى فترات طويلة أكثر من سنة واحدة، قد يزيد بصورة طفيفة من خطر الإصابة بكسور عظام الورك والمعصم أو العمود الفقري.</p><p dir="RTL">يرجى منك إخبار طبيبك المعالج إذا كنت تعاني من هشاشة العظام أو إذا كنت تتناول أياً من الكورتيكوستيرويدات (التي قد تزيد من خطر الإصابة بهشاشة العظام).</p><p dir="RTL">قد يؤثر هذا الدواء على طريقة امتصاص الجسم لفيتامين ب12، خاصةً إذا كنت بحاجة إلى استعمال هذا الدواء لفترة طويلة من الزمن. يرجى منك التواصل مع طبيبك المعالج إذا لاحظت أياً من الأعراض التالية، والتي قد تشير إلى انخفاض مستويات فيتامين ب<sub>12</sub>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الشعور بالتعب الشديد أو فقدان الطاقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الشعور بوخز كوخز الإبر و الدبابيس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; التهاب أو احمرار اللسان، تقرحات في الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ضعف في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; اضطرابات في الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; مشاكل في الذاكرة، الارتباك والاكتئاب.</p><p dir="RTL">عند استخدام أوميبرازول، قد يحدث التهاب في الكلى. قد تشمل العلامات والأعراض على انخفاض في حجم البول أو ظهور دم في البول و / أو تفاعلات فرط الحساسية مثل الحمى والطفح الجلدي وتيبس المفاصل. يجب عليك إخبار طبيبك المعالج بهذه الأعراض.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong><br />يجب عدم إعطاء هذا الدواء للأطفال والمراهقين الذين تقل أعمارهم عن 81 سنة. حيث تعد الخبرة المتوفرة حول استخدام أوميبرازول عن طريق الوريد لدى الأطفال محدودة.</p><p dir="RTL"><strong>استعمال الأدوية الأخرى بالتزامن مع رايسك</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج، الممرض أو الصيدلي الذي تتعامل معه إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أية أدوية أخرى، بما في ذلك الأدوية التي تصرف دون وصفة طبية. حيث أن <strong>رايسك</strong> قد يؤثر على آلية عمل بعض الأدوية، كما أن بعض الأدوية قد يكون لها تأثيرعلى مفعول<strong> رايسك</strong>.</p><p dir="RTL"><strong>يجب عدم إعطاؤك</strong> <strong>رايسك</strong> إذا كنت تتناول أحد الأدوية الحاوية على نلفينافير (يستخدم لعلاج فيروس نقص المناعة البشرية المكتسبة).</p><p dir="RTL"><strong>يجب عليك إخبار طبيبك المعالج، الممرض أو الصيدلي الذي تتعامل معه إذا كنت تتناول أياً من الأدوية التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; كيتوكونازول، إتراكونازول، بوزاكونازول أو فوريكونازول (يستخدم لعلاج العدوى التي تسببها الفطريات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ديجوكسين (لعلاج مشاكل القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ديازيبام (يستخدم لعلاج القلق، مرخي للعضلات أو لعلاج الصرع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; فينيتوين (يستخدم لعلاج الصرع). إذا كنت تتناول فينيتوين، سوف يحتاج طبيبك المعالج لمتابعة حالتك الصحية عند البدء أو التوقف عن استعمال <strong>رايسك</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الأدوية التي تستخدم لترقيق الدم، على سبيل المثال وارفارين أو غالقات مستقبلات فيتامين ك الأخرى. قد يحتاج طبيبك المعالج لمتابعة حالتك الصحية عند البدء أو التوقف عن استعمال <strong>رايسك</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ريفامبيسين (يستخدم لعلاج السل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; أتازانافير (يستخدم لعلاج فيروس نقص المناعة البشرية المكتسبة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تاكروليمس (يستخدم في عمليات زرع الأعضاء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; عشبة سانت جونز ورت (هايبريكم بيرفوراتيم) (تستخدم لعلاج حالات الاكتئاب الطفيفة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; سيلوستازول (يستخدم لعلاج حالات العرج الغير دائم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ساكوينافير (يستخدم لعلاج عدوى فيروس نقص المناعة البشرية المكتسبة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; كلوبيدوجريل (يستخدم لمنع حدوث تجلطات في الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إيرلوتينيب (يستخدم لعلاج السرطان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ميثوتركسيت (علاج كيميائي يستخدم بجرعات كبيرة لعلاج السرطان) - قد يقوم طبيبك المعالج بإيقاف العلاج باستخدام <strong>رايسك</strong> بصورة مؤقتة، إذا كنت تتناول جرعة عالية من ميثوتركسيت</p><p dir="RTL">في حال وصف لك طبيبك المعالج المضادات الحيوية الأموكسيسيلين وكلاريثرومايسين وكذلك <strong>رايسك</strong> لعلاج القرحة الناتجة عن الإصابة بالعدوى الناجمة عن هيليكوباكتر بايلوري، فمن الضروري أن تخبر طبيبك المعالج عن أية أدوية أخرى تتناولها.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية </strong></p><p dir="RTL">يرجى منك استشارة طبيبك المعالج، الممرض أو الصيدلي الذي تتعاملين معه للحصول على المشورة الطبية قبل أن يتم إعطائك هذا الدواء، في حال كنت حاملاً أو ترضعين طفلك رضاعة طبيعية، تعتقدين بأنك حاملاً، أو تخططين لكي تصبحي حاملاً .</p><p dir="RTL">يفرز أوميبرازول في حليب الثدي ولكن لا يرجح أن يؤثر على الطفل عند استخدامه في حدود الجرعات العلاجية.</p><p dir="RTL">سوف يقرر طبيبك المعالج ما إذا كان بإمكانك استعمال <strong>رايسك</strong> إذا كنت ترضعين طفلك رضاعة طبيعية.</p><p dir="RTL"><strong>القيادة واستخدام الآلات&nbsp; </strong></p><p dir="RTL">من غير المرجح أن يؤثر <strong>رايسك</strong> على قدرتك على القيادة أو استخدام الأدوات أو تشغيل الآلات.&nbsp;</p><p dir="RTL">من الممكن حدوث بعض التأثيرات الجانبية على سبيل المثال دوخة واضطرابات في الرؤية (انظر البند رقم 4). يجب عليك عدم القيادة أو تشغيل الآلات، في حال تعرضك لأحد هذه التأثيرات الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن إعطاء <strong>رايسك</strong> للبالغين بما في ذلك فئة كبار السن.</p><p dir="RTL">تعد الخبرة المتوفرة حول استخدام أوميبرازول عن طريق الوريد لدى الأطفال محدودة.</p><p dir="RTL"><strong>عند إعطائك رايسك </strong></p><p dir="RTL">سوف يتم إعطائك <strong>رايسك</strong> من قبل الطبيب المعالج الذي سيقرر لك مقدار الجرعة المطلوبة.</p><p dir="RTL">سوف يعطى لك هذا الدواء عن طريق التسريب في إحدى الأوردة.&nbsp;</p><p dir="RTL"><strong>إذا تم إعطائك رايسك بجرعة أكبر مما يجب </strong></p><p dir="RTL">يرجى منك التحدث إلى طبيبك المعالج على الفور، إذا كنت تعتقد أنه قد تم إعطاؤك <strong>رايسك</strong> بجرعة أكبر مما يجب.</p><p dir="RTL"><strong>يرجى منك استشارة طبيبك المعالج، الممرض أوالصيدلي الذي تتعامل معه، إذا كان لديك أية أسئلة إضافية حول استعمال هذا الدواء. </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو عليه الحال مع جميع الأدوية، قد يتسبب <strong>رايسك</strong> في حدوث تأثيرات جانبية، على الرغم من أنها قد لا تحدث لكل شخص.</p><p dir="RTL"><strong>يرجى منك التوقف عن استعمال رايسك والتواصل مع الطبيب المعالج على الفور، إذا لاحظت أياً من التأثيرات الجانبية النادرة التالية ولكنها خطيرة:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; أزيز مفاجئ، تورم في الشفتين، اللسان والحلق، أو الجسم، طفح جلدي، إغماء أو صعوبة في البلع (تفاعلات تحسسية شديدة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; احمرار الجلد مع ظهور تقرحات أو تقشر في الجلد. قد يظهر أيضاً تقرحات شديدة ونزيف في الشفتين، العينين، الفم، الأنف والأعضاء التناسلية. قد تكون هذه الأعراض والعلامات لحالة تعرف باسم &ldquo;متلازمة ستيفن-جونسون&rdquo; أو &ldquo;انحلال البشرة السمي التنخري&rdquo;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; اصفرار الجلد، بول داكن اللون وتعب، قد تكون هذه الأعراض دلالة على وجود مشاكل في الكبد.</p><p dir="RTL"><strong>التأثيرات الجانبية الأخرى، تتضمن على:</strong></p><p dir="RTL"><strong>التأثيرات الجانبية الشائعة (قد تؤثر على شخص واحد من كل 10 أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تأثيرات على المعدة أو القناة الهضمية: إسهال، ألم في المعدة، إمساك، وغازات في البطن (انتفاخ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ورم حميد في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; شعور بالإعياء (غثيان) أو توعك (تقيؤ)</p><p dir="RTL"><strong>التأثيرات الجانبية الغير شائعة (قد تؤثر على شخص واحد من كل 100 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تورم القدم و الكاحلين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; اضطراب في النوم (أرق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; دوخة، إحساس بالوخز &ldquo; يشبه الوخز بالدبابيس والإبر&rdquo;، شعور بالنعاس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; شعور بالدوار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تغيرات في فحوصات الدم التي تكشف مدى كفاءة وظيفة الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; طفح جلدي، وطفح متكتل (طفح جلدي على شكل خلايا النحل)، وحكة جلدية</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp; </strong>شعور عام بالتعب وفقدان الحيوية والنشاط<strong> </strong></p><p dir="RTL"><strong>التأثيرات الجانبية النادرة (قد تؤثر على شخص واحد من كل 1000 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; مشاكل في الدم على سبيل المثال انخفاض تعداد خلايا الدم البيضاء أو الصفائح الدموية. قد يسبب هذا الأمر الشعور بالضعف، أو ظهور كدمات أو يصبح الجسم أكثر عرضة للإصابة بالعدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تفاعلات تحسسية في بعض الأحيان تكون في غاية الشدة، تتضمن تورم الشفتين، اللسان والحلق، حمى وأزيز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; انخفاض مستوى الصوديوم في الدم، مما قد يسبب ضعف، توعك (تقيؤ) وتقلصات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; شعور بالهياج، ارتباك ، والاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; اضطرابات في حاسة التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; مشاكل في البصر على سبيل المثال عدم وضوح الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; شعور بضيق التنفس أو أزيز بصورة مفاجئة (تشنج قصبي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; التهاب داخل الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الإصابة بعدوى تسمى &ldquo;القلاع&rdquo; الناجمة عن عدوى فطرية والتي يمكن أن تؤثر على القناة الهضمية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; مشاكل في الكبد، بما في ذلك اليرقان الذي قد يسبب اصفرار لون الجلد، بول داكن اللون والشعور بالتعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تساقط الشعر (صلع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; طفح جلدي عند التعرض لأشعة الشمس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ألم في المفاصل أو العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; مشاكل&nbsp; شديدة في الكلى (التهاب الكلية الخلالي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; زيادة التعرق</p><p dir="RTL"><strong>التأثيرات الجانبية النادرة جداً (قد تؤثر على شخص واحد من كل 10000 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تغيرات في تعداد خلايا الدم بما في ذلك نقص الكريات المحببة (نقص كريات الدم البيضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; شعور بالعدوانية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; رؤية أو شعور أو سماع أشياء وهمية ليس لها وجود (هلوسة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; مشاكل شديدة في الكبد قد تؤدي إلى فشل الكبد والتهاب في الدماغ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ظهور طفح شديد أو تقرحات أو تقشر في الجلد بصورة مفاجئة، وقد يصاحب ذلك حمى شديدة وآلام في المفاصل (حمامي متعددة الأشكال، متلازمة ستيفن-جونسون، وانحلال البشرة السمي التنخري)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ضعف العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تضخم الثدي لدى الذكور.</p><p dir="RTL"><strong>التأثيرات الجانبية الغير معروفة (لا يمكن تقدير معدل تكرار حدوثها من البيانات المتاحة):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; التهاب في الأمعاء الذي قد يؤدي إلى حدوث إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; طفح جلدي، ومن المحتمل أن يكون مصحوباً بحدوث ألم في المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كان يتم إعطائك <strong>رايسك</strong> لأكثر من ثلاثة أشهر، فمن الممكن حدوث انخفاض لمستوى المغنيسيوم في الدم. ويمكن ملاحظة هذا الانخفاض لمستوى المغنيسيوم في الدم من خلال ظهور الأعراض التالية: &nbsp; شعور بالتعب، تقلص العضلات اللاإرادية، توهان، تشنجات، دوخة أو زيادة سرعة نبضات القلب. في حال ظهور أياً من هذه الأعراض، يرجى منك إخبار طبيبك المعالج على الفور. إن انخفاض مستوى المغنيسيوم في الدم قد يؤدي أيضاً إلى انخفاض مستوى البوتاسيوم أو الكالسيوم في الدم. قد يقرر طبيبك المعالج إجراء فحوصات للدم بشكل دوري وذلك لمراقبة مستوى المغنيسيوم</p><p dir="RTL">ورد في بعض التقارير حدوث ضعف بصري غير قابل للانعكاس لدى بعض الحالات الفردية للمرضى ذوي الحالات الحرجة الذين تلقوا العلاج باستعمال أوميبرازول<strong> </strong>بواسطة الحقن في الوريد وبصورة خاصة مع الجرعات العلاجية العالية، ولكن لم يتم وضع علاقة سببية توضح حدوث ذلك.</p><p dir="RTL">قد يؤثر أوميبرازول<strong> </strong>في حالات نادرة جداً على خلايا الدم البيضاء مما قد يسبب ضعف المناعة. إذا كنت تعاني من عدوى مصحوبة بأعراض على سبيل المثال الحمى مع تدهور عام وشديد في حالتك الصحية أو كنت تعاني من حمى مصحوبة بأعراض العدوى الموضعية على سبيل المثال ألم في الرقبة، الحلق أو الفم أو صعوبة في التبول، <strong>فيجب عليك استشارة طبيبك المعالج في أسرع وقت ممكن</strong>، حيث يكون بالإمكان إجراء فحص الدم لاستبعاد حدوث نقص في تعداد خلايا الدم البيضاء (نقص الخلايا المحببة). عندئذٍ، من الضروري إخبار طبيبك المعالج عن الأدوية التي تتناولها.</p><p dir="RTL"><strong><u>الإبلاغ عن التأثيرات الجانبية</u></strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض، في حال حدوث أياً من التأثيرات الجانبية، بما في ذلك أية تأثيرات جانبية يحتمل حدوثها ولم يتم ذكرها في هذه النشرة.</p><p dir="RTL">كما يمكنك أيضاً الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق:</p><p dir="RTL"><strong>&bull; &nbsp; </strong><strong>المملكة</strong><strong> </strong><strong>العربية</strong><strong> </strong><strong>السعودية</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ الدوائي:</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp; - رقم الفاكس: </strong>7662-205-11-966+</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp; -</strong> <strong>مركز الاتصال الموحد:</strong> 19999</p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp;&nbsp; - البريد الإلكتروني:</strong>&nbsp; npc.drug@sfda.gov.sa</p><p dir="RTL">&nbsp;<strong>&nbsp;&nbsp;&nbsp; -</strong> ا<strong>لموقع الإلكتروني:</strong> https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp; دول الخليج العربي الأخرى:</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;&nbsp; -</strong> الرجاء الاتصال بالجهات الوطنية في كل دولة.</p><p dir="RTL">إن تسجيل التأثيرات الجانبية يساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp; يحفظ هذا الدواء في مكان آمن بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">-&nbsp;&nbsp; يجب عدم استعمال <strong>رايسك</strong> بعد تاريخ انتهاء الصلاحية المذكور على العبوة أو الملصق الداخلي للزجاجة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">-&nbsp;&nbsp; قبل التحضير، يحفظ في درجة حرارة أقل من 30&deg;م، بعيداً عن الضوء. بعد التحضير، انظر&ldquo;<strong>الاستقرار بعد التحضير</strong>&rdquo;.</p><p dir="RTL">-&nbsp;&nbsp; يجب عدم استعمال <strong>رايسك</strong> إذا لاحظت وجود علامات تلف واضحة.</p><p dir="RTL">-&nbsp;&nbsp; يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي أوميبرازول. تحتوي كل زجاجة على أوميبرازول الصوديوم (مجفف بالتجميد) بما يعادل أوميبرازول 40 ملغم.<strong> </strong></p><p dir="RTL">المواد الأخرى: هيدروكسيد الصوديوم.</p><p dir="RTL"><strong>إن المعلومات التالية تخص أخصائي الرعاية الطبية أو الصحية فقط:</strong></p><p dir="RTL">يتم إذابة محتويات الزجاجة الواحدة من <strong>رايسك</strong> في 5 ملليلتر من المذيب ثم يتم تخفيفها على الفور إلى 100 ملليلتر.</p><p dir="RTL">يجب استخدام محلول كلوريد الصوديوم 9 ملغم/ملليلتر (0,9%) أو محلول دكستروز 50 ملغم/ملليلتر (5%).</p><p dir="RTL">إن مدى استقرار أوميبرازول<strong> </strong>يتأثر بالرقم الهيدروجيني الخاص بالمحلول المستخدم في التسريب، لهذا السبب لا يتم استخدام أية مذيبات أو كميات أخرى للتخفيف.</p><p dir="RTL">يجب إعطاء المحاليل المحضرة عن طريق التسريب الوريدي (خلال 20 - 30 دقيقة).</p><p dir="RTL"><strong><u>طريقة التحضير:</u></strong></p><p dir="RTL">1.&nbsp; يتم باستخدام&nbsp; إحدى الحقن سحب 5 ملليلتر من المحلول الموجود في زجاجة أو كيس التسريب سعة 100ملليلتر.</p><p dir="RTL">2.&nbsp; يتم إضافة الكمية المسحوبة في الحقنة إلى زجاجة <strong>رايسك</strong>، ثم يخلط جيداً للتأكد من ذوبان جميع ما تحتويه الزجاجة من أوميبرازول.</p><p dir="RTL">3.&nbsp; يتم سحب محلول أوميبرازول من زجاجة <strong>رايسك</strong> مرة أخرى بواسطة الحقنة.</p><p dir="RTL">4.&nbsp; انقل محلول أوميبرازول إلى كيس أو زجاجة التسريب.</p><p dir="RTL">5.&nbsp; كرر الخطوات 1 - 4 للتأكد&nbsp; من أنه تم نقل جميع ما تحتويه زجاجة <strong>رايسك</strong> من أوميبرازول إلى زجاجة أو كيس التسريب.</p><p dir="RTL"><strong><u>الجرعة: </u></strong></p><p dir="RTL">يبلغ مقدار الجرعة الموصى بها 40 ملغم مرة واحدة في اليوم. يبلغ مقدار الجرعة الابتدائية الموصى بها لعلاج المرضى الذين يعانون من متلازمة زولينجر إليسون06 ملغم مرة واحدة في اليوم.&nbsp;&nbsp;</p><p dir="RTL">في حال كان مقدار الجرعة يزيد عن 60 ملغم في اليوم، يجب أن يتم تقسيم مقدار الجرعة إلى جرعتين و تعطى مرتين في اليوم.</p><p dir="RTL"><strong>المرضى الذين يعانون من اعتلال في وظائف الكبد:</strong> تعد الجرعة اليومية بمقدار 10 - 20ملغم كافية.</p><p dir="RTL"><strong><u>الإستقرار بعد التحضير:</u></strong></p><p dir="RTL">تبين أن الإستقرار الكيميائي والفيزيائي للمحلول المعد للحقن مدته 12 ساعة إذا تم حفظه في درجة حرارة 30&deg;م بعد تحضيره في محلول كلوريد الصوديوم للتسريب 9 ملغم/ملليلتر (0,9%) ولمدة 6 ساعات إذا تم حفظه في درجة حرارة 30&deg;م بعد تحضيره في محلول دكستروز للتسريب<br />50 ملغم/ملليلتر (5%).</p><p dir="RTL">وفقاً للرؤية الميكروبيولوجية، يجب استخدام المحلول مباشرةً بعد تحضيره، ما لم يكن قد تم تحضيره تحت ظروف معقمة موثوق من صحتها.</p><p dir="RTL">يجب التخلص من الكمية الغير مستخدمة أو الأدوية التي لم تعد بحاجة إليها وفقاً للإجراءات المتبعة محلياً.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">يتوفر <strong>رايسك </strong>في عبوات تحتوي كلاً منها على زجاجة واحدة أو عشر زجاجات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&quot;الخليج للصناعات الدوائية &quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             25/7/2023م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Risek 40 mg Sterile Lyophilized Powder for Solution for Intravenous Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains:
Item No.	Material Name	Scale (mg/vial)
		
	Active Ingredients:	
1.		Omeprazole 	40.000
	Use: Omeprazole Sodium 1	42.600
		
	Inactive Ingredients: 	
1.		Sodium Hydroxide 2	0.232
2.		Water for Injection 3	q.s. to 2 mL

1. Represents the quantity of anhydrous Omeprazole Sodium (100%). This is quantity may vary depending on the potency available during manufacturing.
2. Sodium hydroxide may be used only to adjust the pH of the solution.
3. Water for injection will evaporates during freeze-drying & does not appear in the final product.  

For a full list of excipients, see section 6.1.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sterile lyophilized powder for solution for I.V. infusion.
Description: White or almost white lyophilized powder. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Risek</strong> for intravenous use is indicated in adults, as an alternative to oral therapy for the following indications:</p><p>&sect; Treatment of duodenal ulcers</p><p>&sect; Prevention of relapse of duodenal ulcers</p><p>&sect; Treatment of gastric ulcers</p><p>&sect; Prevention of relapse of gastric ulcers</p><p>&sect; In combination with appropriate antibiotics, <em>Helicobacter pylori (H. pylori) </em>eradication in peptic ulcer disease</p><p>&sect; Treatment of NSAID-associated gastric and duodenal ulcers</p><p>&sect; Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk</p><p>&sect; Treatment of reflux oesophagitis</p><p>&sect; Long-term management of patients with healed reflux oesophagitis</p><p>&sect; Treatment of symptomatic gastro-oesophageal reflux disease</p><p>&sect; Treatment of Zollinger-Ellison syndrome</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p><strong><u>Adults</u></strong></p><p><strong>Alternative to oral therapy</strong></p><p>In patients where the use of oral medicinal products is inappropriate, <strong>Risek</strong> IV 40 mg once daily is recommended. In patients with Zollinger-Ellison Syndrome the recommended initial dose of <strong>Risek </strong>given intravenously is 60 mg daily. Higher daily doses may be required and the dose should be adjusted individually. When doses exceed 60 mg daily, the dose should be divided and given twice daily.</p><p><strong><u>Special populations</u></strong></p><p><strong>Renal impairment</strong></p><p>Dose adjustment is not needed in patients with impaired renal function (see section 5.2).</p><p><strong>Hepatic impairment</strong></p><p>In patients with impaired hepatic function a daily dose of 10-20 mg may be sufficient (see section 5.2).</p><p><strong><u>Elderly</u></strong></p><p>Dose adjustment is not needed in the elderly (see section 5.2).</p><p><strong>Paediatric population</strong></p><p>There is limited experience with omeprazole for intravenous use in children.</p><p><strong><u>Method of administration: </u></strong></p><p><strong>Risek</strong> is to be administered in an intravenous infusion for 20-30 minutes.</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Hypersensitivity to omeprazole, substituted benzimidazoles or to any of the excipients listed in section 6.1.
	Omeprazole like other proton pump inhibitors (PPIs) should not be used concomitantly with nelfinavir (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the presence of any alarm symptom (e.g., significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment may alleviate symptoms and delay diagnosis.</p><p>Co-administration of atazanavir with proton pump inhibitors is not recommended (see section 4.5). If the combination of atazanavir with a proton pump inhibitor is judged unavoidable, close clinical monitoring (e.g virus load) is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; omeprazole 20 mg should not be exceeded.</p><p>Omeprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B<sub>12</sub>&nbsp;(cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B<sub>12</sub>absorption on long-term therapy.</p><p>Omeprazole is a CYP2C19 inhibitor. When starting or ending treatment with omeprazole, the potential for interactions with drugs metabolised through CYP2C19 should be considered. An interaction is observed between clopidogrel and omeprazole (see section 4.5). The clinical relevance of this interaction is uncertain. As a precaution, concomitant use of omeprazole and clopidogrel should be discouraged.</p><p>Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as&nbsp;<em>Salmonella&nbsp;</em>and&nbsp;<em>Campylobacter</em> and, in hospitalised patients, possibly also <em>Clostridium difficile </em>(see section 5.1).</p><p>Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognized risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10&ndash;40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.</p><p><strong><u>Renal impairment</u></strong></p><p>Acute tubulointerstitial nephritis (TIN) has been observed in patients taking omeprazole and may occur at any point during omeprazole therapy (see section 4.8). Acute tubulointerstitial nephritis can progress to renal failure. Omeprazole should be discontinued in case of suspected TIN, and appropriate treatment should be promptly initiated.</p><p><strong><u>Hypomagnesaemia</u></strong></p><p>Severe hypomagnesaemia has been reported in patients treated with proton pump inhibitors (PPIs) like omeprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.</p><p>For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g., diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.</p><p><strong><u>Subacute cutaneous lupus erythematosus (SCLE)</u></strong></p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping omeprazole. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p><strong>Interference with laboratory tests</strong></p><p>Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, Omeprazole treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.</p><p>As in all long-term treatments, especially when exceeding a treatment period of 1 year, patients should be kept under regular surveillance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Effects of omeprazole on the pharmacokinetics of other active substances</u></strong></p><p><strong><u>Active substances with pH dependent absorption</u></strong></p><p>The decreased intragastric acidity during treatment with omeprazole might increase or decrease the absorption of active substances with a gastric pH dependent absorption.</p><p><em>Nelfinavir, atazanavir</em></p><p>The plasma levels of nelfinavir and atazanavir are decreased in case of co-administration with omeprazole.</p><p>Concomitant administration of omeprazole with nelfinavir is contraindicated (see section 4.3).</p><p>Co-administration of omeprazole (40 mg once daily) reduced mean nelvinavir exposure by ca. 40% and the mean exposure of the pharmacologically active metabolite M8 was reduced by ca. 75-90%. The interaction may also involve CYP2C19 inhibition.</p><p>Concomitant administration of omeprazole with atazanavir is not recommended (see section 4.4).</p><p>Concomitant administration of omeprazole (40 mg once daily) and atazanavir 300 mg/ritonavir 100 mg to healthy volunteers resulted in a 75% decrease of the atazanavir exposure. Increasing the atazanavir dose to 400 mg did not compensate for the impact of omeprazole on atazanavir exposure. The co-administration of omeprazole (20 mg once daily) with atazanavir 400 mg/ritonavir 100 mg to healthy volunteers resulted in a decrease of approximately 30% in the atazanavir exposure as compared to atazanavir 300 mg/ritonavir 100 mg once daily.</p><p><em>Digoxin</em></p><p>Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10%. Digoxin toxicity has been rarely reported. However caution should be exercised when omeprazole is given at high doses in elderly patients. Therapeutic drug monitoring of digoxin should be then be reinforced.</p><p><em>Clopidogrel</em></p><p>Results from studies in healthy subjects have shown a pharmacokinetic (PK)/pharmacodynamic (PD) interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and omeprazole (80 mg p.o. daily) resulting in a decreased exposure to the active metabolite of clopidogrel by an average of 46% and a decreased maximum inhibition of (ADP induced) platelet aggregation by an average of 16%.</p><p>Inconsistent data on the clinical implications of a PK/PD interaction of omeprazole in terms of major cardiovascular events have been reported from both observational and clinical studies. As a precaution, concomitant use of omeprazole and clopidogrel should be discouraged (see section 4.4).</p><p><em>Other active substances</em></p><p>The absorption of posaconazole, erlotinib, ketoconazole and itraconazole is significantly reduced and thus clinical efficacy may be impaired. For posaconazole and erlotinib concomitant use should be avoided.</p><p><strong><u>Active substances metabolised by CYP2C19</u></strong></p><p>Omeprazole is a moderate inhibitor of CYP2C19, the major omeprazole metabolising enzyme. Thus, the metabolism of concomitant active substances also metabolised by CYP2C19, may be decreased and the systemic exposure to these substances increased. Examples of such drugs are R-warfarin and other vitamin K antagonists, cilostazol, diazepam and phenytoin.</p><p><em>Cilostazol</em></p><p>Omeprazole, given in doses of 40 mg to healthy subjects in a cross-over study, increased C<sub>max</sub>&nbsp;and AUC for cilostazol by 18% and 26% respectively, and one of its active metabolites by 29% and 69% respectively.</p><p><em>Phenytoin</em></p><p>Monitoring phenytoin plasma concentration is recommended during the first two weeks after initiating omeprazole treatment and, if a phenytoin dose adjustment is made, monitoring and a further dose adjustment should occur upon ending omeprazole treatment.</p><p><strong><u>Unknown mechanism</u></strong></p><p><em>Saquinavir</em></p><p>Concomitant administration of omeprazole with saquinavir/ritonavir resulted in increased plasma levels up to approximately 70% for saquinavir associated with good tolerability in HIV-infected patients.</p><p><em>Tacrolimus</em></p><p>Concomitant administration of omeprazole has been reported to increase the serum levels of tacrolimus. A reinforced monitoring of tacrolimus concentrations as well as renal function (creatinine clearance) should be performed, and dosage of tacrolimus adjusted if needed.</p><p><em>Methotrexate</em></p><p>When given together with proton pump inhibitors, methotrexate levels have been reported to increase in some patients. In high-dose methotrexate administration a temporary withdrawal of omeprazole may need to be considered.</p><p><strong><u>Effects of other active substances on the pharmacokinetics of omeprazole</u></strong></p><p><strong><u>Inhibitors of CYP2C19 and/or CYP3A4</u></strong></p><p>Since omeprazole is metabolised by CYP2C19 and CYP3A4, active substances known to inhibit CYP2C19 or CYP3A4 (such as clarithromycin and voriconazole) may lead to increased omeprazole serum levels by decreasing omeprazole&#39;s rate of metabolism. Concomitant voriconazole treatment resulted in more than doubling of the omeprazole exposure. As high doses of omeprazole have been well-tolerated adjustment of the omeprazole dose is not generally required. However, dose adjustment should be considered in patients with severe hepatic impairment and if long-term treatment is indicated.</p><p><strong><u>Inducers of CYP2C19 and/or CYP3A4</u></strong></p><p>Active substances known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St John&#39;s wort) may lead to decreased omeprazole serum levels by increasing omeprazole&#39;s rate of metabolism.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>Results from three prospective epidemiological studies (more than 1000 exposed outcomes) indicate no adverse effects of omeprazole on pregnancy or on the health of the foetus/newborn child. Omeprazole can be used during pregnancy.</p><p><strong><u>Breast-feeding</u></strong></p><p>Omeprazole is excreted in breast milk but is not likely to influence the child when therapeutic doses are used.</p><p><strong><u>Fertility</u></strong></p><p>Animal studies with the racemic mixture omeprazole, do not indicate effects with respect to fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Omeprazole is not likely to affect the ability to drive or use machines. Adverse drug reactions such as dizziness and visual disturbances may occur (see section 4.8). If affected, patients should not drive or operate machinery.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Summary of the safety profile</u></strong></p><p>The most common side effects (1-10% of patients) are headache, abdominal pain, constipation, diarrhoea, flatulence and nausea/vomiting.</p><p><strong><u>Tabulated list of adverse reactions</u></strong></p><p>The following adverse drug reactions have been identified or suspected in the clinical trials programme for omeprazole and post-marketing. None was found to be dose-related. Adverse reactions listed below are classified according to frequency and System Organ Class (SOC). Frequency categories are defined according to the following convention: Very common (&ge; 1/10), Common (&ge; 1/100 to &lt; 1/10), Uncommon (&ge; 1/1,000 to &lt; 1/100), Rare (&ge; 1/10,000 to &lt; 1/1,000), Very rare (&lt; 1/10,000), Not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:536px"><tbody><tr><td style="vertical-align:top"><p><strong>SOC/frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Leukopenia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Agranulocytosis, pancytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Hypomagnesaemia; severe hypomagnesaemia may result in hypocalcaemia.</p><p>Hypomagnesaemia may also be associated with hypokalaemia</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Agitation, confusion, depression</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Aggression, hallucinations</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dizziness, paraesthesia, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Taste disturbance</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Blurred vision</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Bronchospasm</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Abdominal pain, constipation, diarrhoea, flatulence, nausea/vomiting, fundic gland polyps (benign)</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Dry mouth, stomatitis, gastrointestinal candidiasis</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Microscopic colitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Increased liver enzymes</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hepatitis with or without jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Hepatic failure, encephalopathy in patients with pre-existing liver disease</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dermatitis, pruritus, rash, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Alopecia, photosensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Subacute cutaneous lupus erythematosus (see section 4.4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Fracture of the hip, wrist or spine</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Muscular weakness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Tubulointerstitial nephritis (with possible progression to renal failure)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Gynaecomastia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Malaise, peripheral oedema</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Increased sweating</p></td></tr></tbody></table><p>Irreversible visual impairment has been reported in isolated cases of critically ill patients who have received omeprazole intravenous injection, especially at high doses, but no causal relationship has been established.</p><p>&nbsp;</p><p><strong><u>To report any side effect(s):</u></strong></p><p>&sect; <strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p>&sect; <strong>Other GCC States: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited information available on the effects of overdoses of omeprazole in humans. In the literature, doses of up to 560 mg have been described, and occasional reports have been received when single oral doses have reached up to 2,400 mg omeprazole (120 times the usual recommended clinical dose). Nausea, vomiting, dizziness, abdominal pain, diarrhoea and headache have been reported. Also apathy, depression and confusion have been described in single cases.</p><p>The symptoms described have been transient, and no serious outcome has been reported. The rate of elimination was unchanged (first order kinetics) with increased doses. Treatment, if needed, is symptomatic.</p><p>Intravenous doses of up to 270 mg on a single day and up to 650 mg over a three-day period have been given in clinical trials without any dose-related adverse reactions.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: </strong>Proton pump inhibitors, ATC code: A02BC01</p><p><strong><u>Mechanism of action</u></strong></p><p>Omeprazole, a racemic mixture of two enantiomers reduces gastric acid secretion through a highly targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. It is rapidly acting and provides control through reversible inhibition of gastric acid secretion with once-daily dosing.</p><p>Omeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the intracellular canaliculi within the parietal cell, where it inhibits the enzyme H<sup>+</sup>,K<sup>+</sup>-ATPase - the acid pump. This effect on the final step of the gastric acid formation process is dose-dependent and provides for highly effective inhibition of both basal acid secretion and stimulated acid secretion, irrespective of stimulus.</p><p><strong><u>Pharmacodynamic effects</u></strong></p><p>All pharmacodynamic effects observed can be explained by the effect of omeprazole on acid secretion.</p><p>&nbsp;</p><p><strong>Effect on gastric acid secretion</strong></p><p>Intravenous omeprazole produces a dose dependent inhibition of gastric acid secretion in humans. In order to immediately achieve a similar reduction of intragastric acidity as after repeated dosing with 20 mg orally, a first dose of 40 mg intravenously is recommended. This results in an immediate decrease in intragastric acidity and a mean decrease over 24 hours of approximately 90% for both iv injection and iv infusion.</p><p>The inhibition of acid secretion is related to the area under the plasma concentration-time curve (AUC) of omeprazole and not to the actual plasma concentration at a given time.</p><p>No tachyphylaxis has been observed during treatment with omeprazole.</p><p><strong>Effect on H. pylori</strong></p><p><em>H. pylori</em>&nbsp;is associated with peptic ulcer disease, including duodenal and gastric ulcer disease.&nbsp;<em>H. pylori</em>&nbsp;is a major factor in the development of gastritis.&nbsp;<em>H. pylori</em>&nbsp;together with gastric acid are major factors in the development of peptic ulcer disease.&nbsp;<em>H. pylori</em>&nbsp;is a major factor in the development of atrophic gastritis which is associated with an increased risk of developing gastric cancer.</p><p>Eradication of&nbsp;<em>H. pylori</em>&nbsp;with omeprazole and antimicrobials is associated with high rates of healing and long-term remission of peptic ulcers.</p><p><strong>Other effects related to acid inhibition</strong></p><p>During long-term treatment gastric glandular cysts have been reported in a somewhat increased frequency. These changes are a physiological consequence of pronounced inhibition of acid secretion, are benign and appear to be reversible.</p><p>Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with acid-reducing drugs may lead to slightly increased risk of gastrointestinal infections such as&nbsp;<em>Salmonella</em>&nbsp;and&nbsp;<em>Campylobacter </em>and in hospitalised patients, possibly also <em>Clostridium difficile.</em></p><p>During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours.</p><p>Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.</p><p>An increased number of ECL cells possibly related to the increased serum gastrin levels, have been observed in some patients (both children and adults) during long term treatment with omeprazole. The findings are considered to be of no clinical significance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Distribution</u></strong></p><p>The apparent volume of distribution in healthy subjects is approximately 0.3 l/kg body weight.</p><p>Omeprazole is 97% plasma protein bound.</p><p><strong><u>Biotransformation</u></strong></p><p>Omeprazole is completely metabolised by the cytochrome P450 system (CYP). The major part of its metabolism is dependent on the polymorphically expressed CYP2C19, responsible for the formation of hydroxyomeprazole, the major metabolite in plasma. The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of omeprazole sulphone. As a consequence of high affinity of omeprazole to CYP2C19, there is a potential for competitive inhibition and metabolic drug-drug interactions with other substrates for CYP2C19. However, due to low affinity to CYP3A4, omeprazole has no potential to inhibit the metabolism of other CYP3A4 substrates. In addition, omeprazole lacks an inhibitory effect on the main CYP enzymes.</p><p>Approximately 3% of the Caucasian population and 15&ndash;20% of Asian populations lack a functional CYP2C19 enzyme and are called poor metabolisers. In such individuals the metabolism of omeprazole is probably mainly catalysed by CYP3A4. After repeated once-daily administration of 20 mg omeprazole, the mean AUC was 5 to 10 times higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were also higher, by 3 to 5 times. These findings have no implications for the posology of omeprazole.</p><p><strong><u>Elimination</u></strong></p><p>Total plasma clearance is about 30-40 l/h after a single dose.</p><p>The plasma elimination half-life of omeprazole is usually shorter than one hour both after single and repeated once-daily dosing. Omeprazole is completely eliminated from plasma between doses with no tendency for accumulation during once-daily administration. Almost 80% of a dose of omeprazole is excreted as metabolites in the urine, the remainder in the faeces, primarily originating from bile secretion.</p><p><strong><em>Linearity/non-linearity</em></strong></p><p>The AUC of omeprazole increases with repeated administration. This increase is dose-dependent and results in a non-linear dose-AUC relationship after repeated administration. This time- and dose-dependency is due to a decrease of first pass metabolism and systemic clearance probably caused by an inhibition of the CYP2C19 enzyme by omeprazole and/or its metabolites (e.g the sulphone). No metabolite has been found to have any effect on gastric acid secretion.</p><p><strong><u>Special populations</u></strong></p><p><strong>Hepatic impairment</strong></p><p>The metabolism of omeprazole in patients with liver dysfunction is impaired, resulting in an increased AUC. Omeprazole has not shown any tendency to accumulate with once-daily dosing.</p><p><strong>Renal impairment</strong></p><p>The pharmacokinetics of omeprazole, including systemic bioavailability and elimination rate, are unchanged in patients with reduced renal function.</p><p><strong>Elderly</strong></p><p>The metabolism rate of omeprazole is somewhat reduced in elderly subjects (75-79 years of age).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gastric ECL-cell hyperplasia and carcinoids, have been observed in life-long studies in rats treated with omeprazole. These changes are the result of sustained hypergastrinaemia secondary to acid inhibition.</p><p>Similar findings have been made after treatment with H2-receptor antagonists, proton pump inhibitors and after partial fundectomy. Thus, these changes are not from a direct effect of any individual active substance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Inactive Ingredients:</u></strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium hydroxide<sup>1</sup></p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water for injection<sup>2</sup></p><p>&nbsp;</p><p><sup>1</sup> &nbsp;&nbsp;Sodium hydroxide may be used only to adjust the pH of the solution.</p><p><sup>2.</sup> &nbsp;Water for injection will evaporates during freeze-drying &amp; does not appear in the final<br />&nbsp;&nbsp;&nbsp; product.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product should not be mixed with other medicinal products than those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months from the date of manufacturing.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before reconstitution, store below<em> </em>30&deg;C, protected from light. After reconstitution, see &ldquo;<strong>Stability after Reconstitution</strong>&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect; <strong>Pack of 1 Vial:</strong> Clear glass vial (Flint type I) with a printed label with rubber stopper and flip-off light blue aluminium plastic cap, 1 vial packed in a printed carton along with a leaflet.</p><p>&sect; <strong>Pack of 10 Vials:</strong> Clear glass vial (Flint type I) with a printed label with rubber stopper and flip-off light blue aluminium plastic cap, 10 vials packed in a printed carton along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The entire content of each <strong>Risek</strong> vial is to be dissolved in approximately 5mL and then immediately diluted to 100mL. Sodium chloride 9 mg/mL (0.9%) solution for infusion or dextrose 50 mg/mL (5%) solution for infusion must be used. The stability of omeprazole is influenced by the pH of the solution for infusion, which is why no other solvent or quantities should be used for dilution.</p><p>The reconstituted solutions of <strong>Risek</strong> should be given as an <em>intravenous infusion</em> (over a period of 20 - 30 minutes).</p><p><strong><u>Preparation</u></strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; With a syringe draw 5mL of infusion solution from the 100mL infusion bottle or bag.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add this volume to the <strong>Risek</strong> vial, mix thoroughly making sure all omeprazole is dissolved.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Draw the omeprazole solution back into the syringe.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transfer the solution into the infusion bag or bottle.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Repeat steps 1-4 to make sure all omeprazole is transferred from the vial into the infusion bag or bottle.</p><p><strong><u>Stability after Reconstitution:</u></strong></p><p>Chemical and physical in-use stability has been demonstrated for 12 hours at 30&deg;C, after reconstitution with sodium chloride 9 mg/ml (0.9%) solution for infusion and for 6 hours at 30&deg;C, after reconstitution with dextrose 50 mg/ml (5%) solution for infusion.</p><p>From a microbiological point of view, the product should be used immediately unless it has been reconstituted under controlled and validated aseptic conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street
Ras Al Khaimah - United Arab Emirates
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                25. July. 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>